Trastuzumab Deruxtecan + Pertuzumab Breast Cancer Treatment
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated important weight loss, this benefit was accompanied by a concerning signal regarding cardiovascular safety.
The Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.This translates to a hazard ratio of 1.33,indicating a 33% increased risk. However, it’s crucial to note that the trial did *not* meet its primary endpoint of reducing MACE, despite the significant weight loss observed in the semaglutide group (an average of approximately 15% of body weight).
| Outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| Major Adverse Cardiovascular Event (MACE) | 6.5 | 4.9 | 1.33 |
| Cardiovascular Death | 3.0 | 2.2 | 1.35 |
| Non-Fatal Stroke | 1.7 | 1.3 | 1.31 |
| Non-fatal Heart Attack | 2.6 | 1.8 | 1.44 |
Who is Affected? Understanding the Patient Population
This finding is particularly relevant for individuals with pre-existing cardiovascular disease,including those with a history of heart attack,stroke,or peripheral artery disease. The SELECT trial specifically enrolled participants with established cardiovascular disease, meaning the increased risk wasn’t observed in a generally healthy obese population. It’s critically important to emphasize that this doesn’t necessarily mean semaglutide is risky for *everyone* with obesity, but it does highlight the need for careful risk-benefit assessment.
The trial included participants with a Body Mass Index (BMI) of 27 or higher, and at least one cardiovascular event within the past 24 months. This specific inclusion criteria are vital to understanding the scope of these findings.
Why Does This Matter? The Implications for Clinical Practice
The results of the SELECT trial challenge the widely held belief that semaglutide is a cardiovascularly neutral or even beneficial medication. While weight loss itself is frequently enough associated with improved cardiovascular health, this trial suggests that the drug itself may carry a risk that offsets some of those benefits in vulnerable patients. Clinicians will need to carefully weigh the potential benefits of weight loss against the potential cardiovascular risks when considering semaglutide for patients with established heart disease.